

1 **Digital PCR discriminates between SARS-CoV-2 Omicron variants and immune escape**
2 **mutations**

3 Steven C. Holland¹, LaRinda A. Holland¹, Matthew F. Smith¹, Mihyun B. Lee¹, James C. Hu¹,

4 Efrem S. Lim

5 ¹Center for Fundamental and Applied Microbiomics, Biodesign Institute, Arizona State

6 University

7 ²School of Life Sciences, Arizona State University

8

9 Running title: SARS-CoV-2 variant and immune escape dPCR assays

10

11 #Address correspondence to Efrem S. Lim, Efrem.Lim@asu.edu

12 **ABSTRACT**

13 As SARS-CoV-2 continues to evolve, mutations arise that will allow the virus to evade immune
14 defenses and therapeutics. Assays that can identify these mutations can be used to guide
15 personalized patient treatment plans. Digital PCR (dPCR) is a fast and reliable complement to
16 whole genome sequencing that can be used to discriminate single nucleotide polymorphisms
17 (SNPs) in template molecules. Here, we developed a panel of SARS-CoV-2 dPCR assays and
18 demonstrate its applications for typing variant lineages and therapeutic monoclonal antibody
19 resistance. We designed multiplexed dPCR assays for SNPs located at residue 3395 in the *orf1ab*
20 gene and residue 143 of the *spike* gene that differentiate the Delta, Omicron BA.1, and Omicron
21 BA.2 lineages. We demonstrate their validity on 596 clinical saliva specimens that were
22 sequence-verified using Illumina whole genome sequencing. Next, we developed dPCR assays
23 for spike mutations R346T, K444T, N460K, F486V, and F486S mutations that are associated with
24 host immune evasion and reduced therapeutic monoclonal antibody efficacy. We demonstrate
25 that these assays can be run individually or multiplexed to detect the presence of up to 4 SNPs
26 in a single assay. We validate these dPCR assays on 81 clinical saliva SARS-CoV-2 positive
27 specimens from Omicron subvariants BA.2.75.2, BM.1.1, BN.1, BF.7, BQ.1, BQ.1.1, and XBB.
28 Thus, dPCR could serve as a useful tool to determine if clinical specimens contain
29 therapeutically relevant mutations and inform patient treatment.

30

31 **Keywords**

32 SARS-CoV-2, Digital PCR, monoclonal antibody, immune escape mutations, clinical diagnostics

33 INTRODUCTION

34 The evolution of SARS-CoV-2 brings challenges to disease epidemiology and patient treatment.

35 Genomic mutations arise that define phylogenetic lineages, alter virus properties, and have

36 functional consequences of clinical significance (1). In early November, 2021, the SARS-CoV-2

37 Delta variant and its sublineages were the predominantly circulating lineages in the United

38 States (2). On November 26, 2021 the World Health Organization designated the SARS-CoV-2

39 Omicron variant as a “variant of concern” (3). Genome sequencing showed that the Omicron

40 lineages contained approximately 50 unique mutations compared to previous variants of

41 concern (4). Phylogenetic analysis indicated that the Omicron lineages arose independent of

42 the Delta lineage, likely from a prolonged infection in an immunocompromised patient, or an

43 animal host (5). The Omicron BA.1 lineage eventually rose to be the dominant circulating

44 lineage, displacing Delta lineages at a rate faster than previous variants (6). This increased rate

45 of displacement is likely due to increased immune evasion and infectivity of the early Omicron

46 BA.1 and BA.2 variants (7-9).

47 Since their initial emergence, Omicron lineages have diversified, with multiple sublineages

48 branching from the ancestral BA.1 and BA.2 lineages. Studies show that currently circulating

49 strains (e.g. BA.2.75.2 and BQ.1.1) are increasingly able to escape neutralization by sera

50 obtained from vaccinated individuals, compared to the original BA.2 strain (10). Neutralization

51 by sera from vaccinated individuals that also recovered from an Omicron breakthrough

52 infection (BA.1, BA.2, or BA.5) was also reduced in more recent variants. Worryingly, circulating

53 sublineages have also independently evolved mutations within the receptor binding domain

54 (RBD) of the Spike protein that escape neutralization by the therapeutic monoclonal antibodies

55 (mAbs) bebtelovimab, bamlanivimab, etesevimab, casirivimab, tixagevimab, and others (11).
56 The R346, K444, L452, N460, E484, and F486 residues may be particularly important in mAb
57 resistance and SARS-CoV-2 pathology (12). Due to the limited methods to determine if a patient
58 is infected with a resistant variant, the FDA issues blanket guidance to withdraw emergency use
59 authorization (EUA) for mAbs based on general variant presence (13). This significantly limits
60 patient access to life-saving treatment options regardless of what variant they are infected with
61 (e.g., co-circulating variants that are susceptible to mAbs). Hence, methods to rapidly
62 determine if SARS-CoV-2 positive patient specimens harbor resistance mutations are of critical
63 importance in guiding therapeutic treatment.

64 Whole genome sequencing is the most comprehensive method for genotyping SARS-CoV-2.
65 However, the cost, time requirements, and required technical expertise leaves a need for
66 complementary methods to identify variants of concern and mutations of interest in clinical
67 specimens. Digital PCR (dPCR) has emerged as a technology that can be used to detect and
68 differentiate single nucleotide polymorphisms (SNPs) in template DNA (14). In the QuantStudio
69 Absolute Q Digital PCR system (ThermoFisher, Massachusetts, USA), template DNA is
70 partitioned into over 20,480 microchambers. Within each microchamber, an end-point PCR
71 reaction is performed which contains primers and probes specific to template DNA. TaqMan
72 (ThermoFisher, Massachusetts, USA) probes contain a fluorescent dye and fluorescent
73 quencher molecule affixed to opposing ends of the probe oligomers. During the PCR elongation
74 phase, polymerase activity degrades annealed probes, liberating the fluorescent dye from the
75 quencher molecule and allowing fluorescence emission (15). Probe length is an important
76 factor in facilitating fluorescence quenching, so minor groove binder (MGB) moieties can also

77 be attached to probes to reduce probe length and improve quencher efficiency (16). After the
78 PCR assay has completed, end-point fluorescence intensity is then used to determine whether a
79 microchamber is 'positive' or 'negative' for each probe target and the number of positive
80 microchambers can be used to calculate template presence (17). The robustness and sensitivity
81 of dPCR to detect template differences of only a single nucleotide have made it useful in
82 practical applications of viral identification and quantitation, determination of allelic imbalance,
83 and wastewater viral variant surveillance (18-20).

84 In this study, we demonstrate the usefulness of dPCR in detecting polymorphisms in SARS-CoV-
85 2 genomes obtained from clinical saliva specimens. We show that dPCR can detect the
86 presence of one or two SNPs to distinguish between the Delta, Omicron BA.1, and Omicron
87 BA.2 lineages. We also show that a nine-nucleotide deletion can be used to identify the
88 Omicron BA.1 lineage. We verify the clinical validity of these assays by determining lineage
89 designations for 596 SARS-CoV-2 positive clinical saliva samples and verify those determinations
90 by Illumina next generation sequencing. We finally demonstrate the ability of dPCR to identify
91 mutations at up to 4 genomic loci in a single reaction vessel and use this ability to detect SNPs
92 associated with immune escape in 81 clinical saliva samples.

93 **MATERIALS AND METHODS**

94 **Saliva specimens and diagnostic testing**

95 This study was approved by Arizona State University Institutional Review Board. This study
96 involved analyses of 677 saliva specimens submitted for SARS-CoV-2 testing at ASU Biodesign
97 Clinical Testing Laboratory (ABCTL) from November 16, 2021 to December 10, 2022. Saliva

98 samples were independently collected by participants in 2 mL collection vials, registered, and
99 deposited at drop-off locations. RNA was extracted from 250µl of saliva specimen within 33
100 hours of sample receipt using the KingFisher Flex (Thermo Scientific), following the
101 manufacturer’s guidelines. Diagnostic testing was performed using TaqPath COVID-19 Combo
102 Kit assay (Applied Bio-systems, USA) following manufacturer’s guidelines.

103 **Digital PCR**

104 DNA constructs (primers, probes, template constructs) were ordered from either Integrated
105 DNA technologies (Coralville, IA, USA) or Applied Biosystems (Waltham, MA, USA; nucleotide
106 sequences can be found in Tables S1, S2, and S3 in the supplemental material).

107 The reaction mixtures for the *orf1ab* and *spike* lineage discriminating assays were comprised of
108 1X Absolute Q 1-step RT-dPCR Master Mix (Applied Biosystems, Waltham, MA), 400 nM of each
109 primer, 200 nM of each fluorescent probe, 4 µL template, water was used to bring the final
110 volume to 9µL. Synthetic DNAs were assayed at a concentration of 10³ copies/µL. Saliva
111 specimens with threshold cycle (C_t) values less than 19 when assayed using TaqPath COVID-19
112 Combo Kit assay (Applied Bio-systems, USA) were diluted 1:2 before loading.

113 The reaction mixtures for the *spike* RBD mutation assays were comprised of 1X Absolute Q 1-
114 step RT-dPCR Master Mix (Applied Biosystems, Waltham, MA), 450 nM of each primer, 280 nM
115 of each fluorescent probe, 5.5 µL template, water was used to bring the final volume to 9µL.
116 Synthetic DNAs were assayed at a concentration of 10³ copies/µL.

117 Samples were loaded in QuantStudio Absolute Q MAP16 (Applied Biosystems, Waltham, MA),
118 overlaid with 15 µL Absolute Q Isolation Buffer (Applied Biosystems, Waltham, MA), and the

119 digital PCR reactions were performed on the Absolute Q dPCR system (Applied Biosystems,
120 Waltham, MA). For the *orf1ab* and *spike* lineage determination assays, cycling conditions were:
121 10 min at 50°C, 5 min activation at 95°C, 40 cycles of 2s at 95°C and 15s at 54°C. For the *spike*
122 RBD assay determination assays, cycling conditions were: 10 min at 50°C, 5 min activation at
123 95°C, 40 cycles of 2s at 95°C and 25s at 58°C. Fluorescence intensities and positive chamber
124 counts were analyzed using QuantStudio Absolute Q Digital PCR Software version 6.2.0 (Applied
125 Biosystems, Waltham, MA). Results for clinical specimens can be found in the supplemental
126 material datasets 1 - 5.

127 **SARS-CoV-2 genome sequencing**

128 NGS library preparation for saliva samples was performed using the COVIDSeq Test
129 (Illumina, San Diego, CA, USA) with ARTICv4 and ARTICv4.1 primer sets (21). Libraries were
130 sequenced on the Illumina NextSeq2000 instrument using 2 × 109 paired end reads. Sequencing
131 reads adapter sequences were trimmed using trim-galore, aligned to the Wuhan1 reference
132 genome (MN908947.3) using the Burrows–Wheeler aligner, BWA-MEM version 0.7.17-r1188
133 (22), and had their primer sequences trimmed using iVar version 1.3.1 (23). Lineage calling for
134 community and hospital-derived sequencing data was performed with pangolin software (24),
135 with its assignment and designation libraries up to date at the time of analysis. Sequence
136 quality was validated and annotated using VADR version 1.4 (25).

137 **Phylogenetic analysis**

138 Phylogenies were generated using Nextstrain.cli version 5.0.1 (26) and associated Augur
139 Auspice pipeline with an input dataset based on the Nextstrain ncov GISAID Reference dataset

140 accessed on November 16th, 2022. Duplicate lineages were removed, and the set was
141 supplemented with lineages of interest in which assay-targeted mutations were found to be
142 present in at least 75% of sequences. The Nextstrain nCoV default build was utilized, with a
143 minimal config file specifying the input dataset and Wuhan/Hu-1/2019 as the root. The filter
144 settings in the default parameters file were modified by setting the skip_diagnostics flag to
145 *true*.

146 **Global mutation proportion analysis**

147 Global mutation proportion data were downloaded from cov-spectrum (27) with simple queries
148 for S:R346T, S:K444T, S:N460K, S:F486S, and S:F486V. Absolute counts were downloaded in
149 addition to proportion data for S:N460K. An advanced query was performed to obtain absolute
150 counts for each codon (AAA, AAG) present in S:N460K sequences. Data were plotted from
151 March 3rd, 2022 until November 6th, 2022. For plotted data range, the difference in 95% CI top
152 and 95% CI bottom never reaches greater than 5%)

153

154 **RESULTS**


155 **Digital PCR assay to distinguish Delta, Omicron BA.1, and Omicron BA.2 utilizing two SNPs in** 156 **the *orf1ab* gene.**

157 Since the effectiveness of therapeutic treatments can differ between SARS-CoV-2 lineages, a set
158 of dPCR probes was designed to discriminate between the Delta, Omicron BA.1, and BA.2
159 lineages using SNPs found in the *orf1ab* gene (**Fig 1A**). The probes hybridize at nucleotides

160 10440-10454, located in the *orf1ab* gene, and are used to detect substitutions found in the
161 Delta and Omicron lineages located at amino acids R3394 and P3395. The probe homologous to
162 the Delta lineage sequence uses VIC as its fluorescent dye and shares the same nucleotide
163 sequence as the Wuhan1 reference sequence over the probe region. The Omicron BA.1 probe
164 discriminates between the Delta sequence at the c10449a nucleotide substitution (amino acid
165 P3395H) and uses FAM as its fluorescent dye. The Omicron BA.2 probe discriminates between
166 the Delta sequence at the c10449a (amino acid P3395H) and g10447a (synonymous mutation in
167 R3394) nucleotide substitutions and uses NED as its fluorescent dye. The fluorescent dyes were
168 connected to the 5' end of the oligo and all three probes contain a minor groove binder (MGB)
169 moiety on the 3' end of the oligo to improve binding to template sequence (15).

170 The efficacy and specificity of probes were tested using synthetic DNA constructs (**Fig 1B**). The
171 Delta (VIC), Omicron BA.1 (FAM), and Omicron BA.2 (NED) probes showed a clear fluorescence
172 response when assayed with their homologous templates. The Omicron BA.1 probe also
173 showed a fluorescence response to the Delta and Omicron BA.2 templates. This signal was
174 lower in fluorescence intensity than observed from Omicron BA.1 templates, but higher than
175 the negative signal observed in reactions containing no template DNA. There was a negligible
176 response of the Delta (VIC) and Omicron BA.2 (NED) probes when used on their mismatching
177 templates. Fluorescence threshold values for each probe were set to exclude the range of
178 negative values found in mismatching templates. The fluorescence threshold for Omicron BA.1
179 (FAM) was set above the non-specific fluorescence values observed in the mismatching
180 template assays.

181 In order to determine the validity of the *orf1ab* dPCR assay on clinical specimens, we performed
182 the 3-probe multiplex dPCR assay and Illumina next-generation sequencing on 596 SARS-CoV-2
183 positive saliva samples. To receive a ‘positive’ result for a particular probe, the sample required
184 9 or more microchambers to have a fluorescence intensity above the threshold value. During
185 the dPCR assay scoring, Illumina sample lineages were blinded to scorers. Using this criteria,
186 540 samples tested positive for a single lineage using the dPCR assay. All 540 samples had
187 lineage designations by dPCR concordant with Illumina whole genome sequencing designations.
188 No samples displayed a positive response from probes discordant to the genome sequencing
189 designations (**Fig 1C**; also see Supplementary Dataset
190 1 in the supplemental material). There were 56 samples in which no probe passed the positive
191 chamber count. C_t values of these negative samples were found to be significantly higher than
192 samples with positive outcomes, indicating that viral load contributes to assay efficacy (Positive
193 samples median C_t = 22.05, Negative samples median C_t = 24.34, $p < 0.0001$; Mann-Whitney
194 test). Together, this demonstrates that dPCR can use two nucleotide polymorphisms to
195 discriminate the Delta, Omicron BA.1, and Omicron BA.2 lineages in saliva specimens.



196

197 **Fig 1:** Digital PCR assay for the determination of the Delta, Omicron BA.1, and Omicron BA.2

198 lineages. (A) Schematic showing annealing locations of primers (black arrows) and probes

199 (colored boxes) on the SARS-CoV-2 genome. (B) Representative fluorescence intensities of dPCR

200 microchambers for synthetic DNA constructs. Positive microchambers are those exceeding

201 fluorescence thresholds (shaded regions). (C) Number of positive microchambers (maximum

202 number of chambers is 20480) resulting from each saliva sample. Samples are grouped by

203 Illumina sequencing lineage determination and sorted by positive microchamber count of the

204 respective lineage-specific probe. Dotted line indicates the positive threshold value (9

205 microchambers).

206


207 **Digital PCR assay to distinguish between Omicron BA.1 and Delta/Omicron BA.2 utilizing a**
208 **nine-nucleotide deletion in the *spike* gene.**

209 Some therapeutic antibodies, like sotrovimab, are still partially effective against the Omicron
210 BA.1 lineage but less effective against the BA.2 lineage (11), we sought to design an assay to
211 discriminate the Omicron BA.1 lineage from Delta and BA.2. We found a nine-nucleotide
212 deletion within the Spike protein coding region (G21987-T21995, amino acids G142-Y145)
213 specific to the BA.1 lineage. We designed dPCR probes to either contain only the nucleotides
214 flanking the deleted region or to contain the nucleotides found in the deletion (**Fig 2A**). These
215 sequences would provide identity to the Omicron BA.1 lineage, or to the Delta and Omicron
216 BA.2 lineages, respectively. Probes contained either the VIC (BA.1) or FAM (Delta/BA.2)
217 fluorescent dye on the 5' end and both probes contained a 3' MGB moiety.

218 The dPCR probes were validated on synthetically produced DNA templates. Each probe
219 displayed a high fluorescence signal when assayed with its matching template (**Fig 2B**). No
220 evidence of a secondary fluorescence signal band, as seen in the *orf1ab* Omicron BA.1 probe
221 (**Fig 1B**), was observed in either probe (**Fig 2B**). Fluorescence thresholds were set by excluding
222 fluorescence intensity values from mismatching control templates.

223 The S gene dPCR assay was performed on the same 596 SARS-CoV-2 positive clinical saliva
224 samples assayed on the *orf1ab* assay. Sample positivity was scored as above, blinded and using
225 the 9 microchambers as the positive threshold criterion. Using this method, 512 samples tested
226 positive from a single probe. All 512 lineage designations from Illumina whole genome
227 sequencing were in concordance with the digital PCR assay. No sample tested positive to a

228 dPCR probe that was discordant to its lineage designation from whole genome sequencing (**Fig**
 229 **2C**; also see Supplementary Dataset 2 in the supplemental material). There were 84 samples in
 230 which no probe passed the positive threshold value. C_t values of samples with no positive
 231 results were found to be significantly higher than positive samples, indicating that viral load
 232 contributes to assay efficacy (Positive samples median $C_t = 21.88$, Negative samples median $C_t =$
 233 24.42 , $p < 0.0001$; Mann-Whitney test). This demonstrates that the S gene del143-145 deletion
 234 can be used to discriminate SARS-CoV-2 Omicron BA.1 lineages from Delta and Omicron BA.2
 235 lineages in saliva specimens.



236
 237 **Fig 2:** Digital PCR assay for the determination of the Omicron BA.1, and Delta or Omicron BA.2
 238 lineages. (A) Schematic showing annealing locations of primers (black arrows) and probes
 239 (colored boxes) on the SARS-CoV-2 genome. (B) Representative fluorescence intensities of dPCR
 240 microchambers for synthetic DNA constructs. Positive microchambers are those exceeding

241 fluorescence thresholds (shaded regions). (C) Number of positive microchambers (maximum
242 number of chambers is 20480) resulting from each saliva sample. Samples are grouped by
243 Illumina sequencing lineage determination and sorted by positive microchamber count of the
244 respective lineage-specific probe. Dotted line indicates the positive threshold value (9
245 microchambers).

246


247 **Digital PCR assays to detect immune evasion-associated SNPs in the Spike protein receptor**
248 **binding domain.**

249 Another potential diagnostic application is in discerning the presence of amino acid mutations
250 that may render therapeutic monoclonal antibodies ineffective. To observe the frequency of
251 Spike RBD mutations that provide immune escape properties, the GISAID database was queried
252 for SARS-CoV-2 Omicron sequences containing five mutations associated with immune escape:
253 R346T, K444T, N460K, F486V, and F486S (10) (**Fig 3**). The L452R mutation within the Spike RBD
254 region has also been strongly associated with immune escape (10), but has been the subject RT-
255 qPCR detection (28), so it was omitted from analysis. We found that many of these mutations
256 are found distributed across multiple sublineages (**Fig 3A**). We observed that the R346T
257 mutation has been rising in frequency since May 2022 and has arisen in the BA.2, BA.4, and
258 BA.5 lineages as well as in the XBB recombinant lineages (**Fig 3B**). The K444T mutation has been
259 rising in global frequency since September 2022, arising within the BE and BQ sublineages (BE
260 and BQ are sublineages of BA.5; **Fig 3C**). The N460K mutation has arisen within BA.2 and BA.5
261 sublineages and XBB recombinants (**Fig 3D**). The BA.2 sublineages utilize an AAG codon,

262 whereas the BA.5 lineages utilize an AAA codon. The F486S mutation is slowly becoming more
263 abundant and is seen in BA.2 sublineages and XBB recombinants (**Fig 3E**). The F486V mutation
264 arose earliest and differentiates BA.4 and BA.5 lineages from BA.2 lineages (**Fig 3F**). Taken
265 together, these mutations are becoming more abundant in circulating SARS-CoV-2 lineages and
266 are arising in multiple, independent lineages.

267 To ensure that dPCR probes were designed with sequences representative of circulating SARS-
268 CoV-2 genomes, we queried the GISAID database to determine the codon usage for amino acid
269 mutations associated with immune escape. For the R346T, K444T, F486V and F486S mutations,
270 over 99% of genome sequences in the GISAID database utilize a single codon to encode the
271 substituted amino acid (**Figs 3A, 3B, 3C, 3E, 3F**). However, N460K is encoded by the AAG codon
272 in 54.09% of sequences and by the AAA codon in 45.91% of genomes containing this mutation
273 (**Fig 3D**). Therefore, two probes were designed to investigate the N460K mutation. Probes
274 containing the amino acid found in the Wuhan1 reference sequence at each position were also
275 created at each position. To assess the global applicability of the dPCR assays, we calculated the
276 mismatch frequency at each nucleotide position for all primers and probes against all genome
277 sequences in the GISAID database. We found that probes had low mismatch frequency outside
278 of the codon encoding the mutation of interest (see Fig S1 in the supplemental material).
279 Primers also had a low mismatch frequency, however, the F486 assay requires the presence of
280 the S477N and T478K mutations for amplicon generation.

It is made available under a [CC-BY-NC-ND 4.0 International license](https://creativecommons.org/licenses/by-nc-nd/4.0/).



281

282 **Fig 3:** Phylogenetic distribution of mutations that evade therapeutic monoclonal antibodies. (A)

283 Phylogenetic tree of representative circulating sublineages. Colored circles indicate the

284 presence of a Spike RBD mutation found in at least 75% of sequences within that lineage.


285 Global frequency, phylogenetic distribution, and codon frequencies for R346T (B), K444T (C),
286 N460K (D), F486S (E), and F486V (F) mutations.

287

288 Mutation and reference probes were designed to be run independently or multiplexed with
289 other probes. Each mutation/reference pair contained a different fluorescent dye and the
290 mutation probes used a different fluorescent dye between residue locations (**Fig 4A**). Mutation
291 probes for sites containing two mutations (i.e. N460K (AAA) and N460K (AAG), F486S and
292 F486V) use the same fluorescent dye for each mutation. The R346 and F486 probe sets use
293 unique, independent amplicons, whereas the K444 and N460 probe sets share a single,
294 common amplicon.

295 In order to determine the effectiveness of the dPCR probes to discriminate the identity of each
296 SNP, reactions containing the probe homologous to the mutation of interest and a probe
297 homologous to the reference sequence were assayed in a single reaction vessel. Each probe
298 pair was assayed using synthetically produced DNA templates containing the mutation
299 nucleotide sequence or reference nucleotide sequence. For each reaction, each probe
300 displayed a higher fluorescence signal to its homologous template, than to a template
301 containing a mismatching nucleotide (**Fig 4B**). Positive FAM fluorescence was observed from
302 assays with templates containing N460 or K444T residues. Positive VIC fluorescence was
303 observed from assays with templates containing N460K or K444 residues. Positive ABY
304 fluorescence was observed from assays with templates containing R346T or F486 residues.
305 Positive JUN fluorescence was observed from assays using templates containing R346, F486S, or

306 F486V templates. Together, this demonstrates that each probe can correctly discriminate
 307 templates differing by only a single SNP within the probe region.



308
 309 **Fig 4:** Digital PCR assay for the detection of mutations associated with therapeutic monoclonal
 310 antibody evasion. (A) Schematic showing annealing locations of primers (black arrows) and
 311 probes (colored boxes) on the SARS-CoV-2 genome. (B) Representative fluorescence intensities
 312 of dPCR microchambers for synthetic DNA constructs. Positive microchambers are those
 313 exceeding fluorescence thresholds (shaded regions).


314

315 The primers and probes from two assays were combined to assay the identity of two SNPs from
316 a single template. For each reaction, two amplicons were produced, with each amplicon
317 containing only a single substitution of interest. When assayed on synthetic DNA constructs,
318 each probe in the assays displayed higher fluorescence to its homologous template, than to a
319 mismatching template. The R346 and K444 assays were combined into single dPCR assay to
320 interrogate sequence identity at those positions simultaneously (**Fig 5A**). On the template
321 containing reference sequences, positive fluorescence was observed in VIC and JUN channels. A
322 positive response was observed in FAM and ABY channels for a template containing K444T and
323 R346T mutations, respectively.

324 The N460 and F486 assays were also combined into a single assay (**Fig 5B**). The reaction
325 contained a labeled probe for each reference sequence, a VIC-labeled probe for each N460K
326 codon (AAG and AAA), and a JUN-labeled probe for each F486 mutation (F486S and F486V). For
327 the reference sequence template, positive fluorescence responses were observed in the FAM
328 and ABY channels, and for both mutation templates positive responses were observed in the
329 VIC and JUN channels. An equivalent positive response was observed for the N460K AAG and
330 AAA codon probes as well as between the F486S and F486V probes, for their respective
331 templates.

332 The presence or absence of mutations at 4 SNP sites was able to be resolved in a single dPCR
333 reaction by using the mutation specific probes containing a different fluorescent dye for each
334 locus. Three amplicons were produced in each reaction, with the K444 and N460 probes sharing
335 an amplicon. For each probe, fluorescence values were higher for its homologous template
336 than to its mismatching template (**Fig 5C**). No positive response from any channel was observed

337 to a template containing the reference sequence at each position. Positive responses in the VIC,
338 ABY, and JUN channels were observed on a template containing N460K (AAG), R346T, and
339 F486V mutations. Positive responses in all four channels were observed on a template
340 containing the K444T, N460K (AAA), R346T, and F486S mutations. The number of positive
341 microchambers were similar between templates and probes, excepting the R346T probe having
342 a lower positive chamber count. These results demonstrate the versatility of dPCR assays to
343 report the identity of multiple nucleotide sequences across a template.



345 **Fig 5:** Representative microchamber fluorescence intensities for synthetic DNA constructs from
346 multiplexed dPCR assays. (A) R346 and K444 combination assay. (B) N460 and F486
347 combination assay. (C) Combination assay using R346T, K444T, N460K (AAA and AAG codons),
348 F486S, and F486V mutation probes. Positive microchambers are those exceeding fluorescence
349 thresholds (shaded regions).

350

351 In order to test the validity of these multiplexed RT-dPCR assays on clinical samples, we
352 performed dPCR and Illumina sequencing assays on human saliva samples. Saliva samples
353 containing SARS-CoV-2 infections from 8 lineages, previously identified by Illumina whole
354 genome sequencing, were used to evaluate the specificity of the assay to discriminate among
355 clinical specimens with varying mutation profiles. For each lineage, samples were examined
356 using an assay where the R346 and K444 assays were combined, an assay where the N460 and
357 F486 assays were combined, and an assay where all 6 mutation-specific probes were used.

358 The combined R346 and K444 assay was able to correctly discriminate between the mutation
359 and reference sequence at each locus (**Fig 6A**). FAM fluorescence was observed in the BQ.1 and
360 BQ.1.1 lineages, which contain the K444T mutation. Positive VIC fluorescence was seen in
361 samples from the BA.2, BA.2.75.2, BM.1.1, BN.1, BA.5, and BF.7 lineages, consistent with the
362 presence of the reference sequence at the K444 locus. While the XBB lineage contains the
363 reference amino acid at K444 and V445P mutation. The V445P mutation is not present in the
364 reference-specific probe and causes failure at this position. A positive ABY response was seen in
365 the BA.2.75.2, BM.1.1, BN.1, BF.7, BQ.1.1, and XBB lineages, which contain the R346 mutation.
366 Finally, JUN fluorescence properly identified the presence of the reference sequence at R346 in
367 the BA.2, BA.5, and BQ.1 lineages. A reduced positivity response of the R346 probes was also
368 observed on the saliva samples, as seen with the synthetic DNA constructs. Thirty-two total
369 samples were tested on the combined assay and gave results consistent with their Illumina
370 whole genome sequencing determination (see Supplementary Dataset 3 in the supplemental
371 material).


372 Sequence composition of saliva samples was correctly identified using the N460 and F486
373 combined assays (**Fig 6B**). Positive FAM fluorescence was observed in the BA.2, BA.5, and BF.7
374 lineages, which contain the reference nucleotide sequence at N460. Positive VIC fluorescence
375 was observed in the BA.2.75.2, BM.1.1, BN.1, BQ.1, BQ.1.1, and XBB lineages, consistent with
376 the presence of the N460K mutation in these lineages. Positive ABY fluorescence was observed
377 in the BA.2 and BA.5 lineages, which have the reference nucleotide sequence at F486. Positive
378 JUN fluorescence was observed in BA.2.75.2, BM.1.1, BA.5, BF.7, BQ.1, BQ.1.1, and XBB
379 lineages, which contain either the F486S or F486V mutations. Twenty-eight total samples were
380 tested on the combined assay and gave results consistent with their Illumina whole genome
381 sequencing determination (see Supplementary Dataset 4 in the supplemental material).

382 An assay comprised of the 6 mutation-specific probes was also verified on saliva samples and
383 gave appropriate responses to mutation composition (**Fig 6C**). Positive FAM fluorescence was
384 observed in the BQ.1 and BQ.1.1 lineages, consistent with the presence of the K444T mutation.
385 Positive VIC fluorescence was observed in the BA.2.75.2, BM.1.1, BN.1, BQ.1, BQ.1.1, and XBB
386 lineages, consistent with the presence of either N460K mutation (AAG or AAA codon). Positive
387 ABY fluorescence was observed in the BA.2.75.2, BM.1.1, BN.1, BF.7, BQ.1.1, and XBB lineages,
388 consistent with the presence of the R346T mutation. Positive JUN fluorescence was observed in
389 the BA.2.75.2, BM.1.1, BA.5, BF.7, BQ.1, BQ.1.1, and XBB lineages, consistent with the presence
390 of either the F486S or F486V mutations. No positive fluorescence response was observed in the
391 BA.2 lineage, which contains none of the screened mutations. As in the R346/K444 combination
392 assay, the XBB lineage failed to display FAM fluorescence due to the absence of the K444T
393 mutation and the presence of the V445P mutation. We tested this assay on 75 total saliva


394 samples, and all samples displayed results consistent with their respective Illumina whole
395 genome sequencing lineage designation (see Supplementary Dataset 5 in the supplemental
396 material). These assays illustrate that dPCR can discern immunologically relevant SARS-CoV-2
397 mutations from saliva specimens and could be used to guide therapeutic treatment.

Figure 6


A R346/K444 probes



B N460/F486 probes



C 6 mutation probes (R346T, K444T, N460K (AAG), N460K (AAA), F486S, F486V)



399 **Fig 6:** Representative microchamber fluorescence intensities for clinical saliva specimens from
400 multiplexed dPCR assays. (A) R346 and K444 combination assay. (B) N460 and F486
401 combination assay. (C) Combination assay using R346T, K444T, N460K (AAA and AAG codons),
402 F486S, and F486V mutation probes. Positive microchambers are those exceeding fluorescence
403 thresholds (shaded regions).

404

405 **DISCUSSION**

406 In this study we demonstrated the robustness of using digital PCR in genotyping SARS-CoV-2
407 positive saliva samples for two use cases: lineage classification and therapeutic mAb resistance.
408 We showed that using a mixture of probes with a common fluorescent dye can be used to
409 identify mutants when multiple nucleotide substitutions are at one region of interest (N460 and
410 F486 assays, **Fig 4B**). This is particularly useful when an amino acid is encoded by multiple
411 codons, or multiple amino acids are of interest. We also demonstrated that detection is not
412 compromised when multiple probes bind to different locations on a single amplicon
413 (N460/F486 assay, **Fig 5C**). This property is beneficial when interrogating multiple mutations
414 within a single domain of a protein (e.g. the RBD of the *s* gene) where creating multiple
415 amplicons could be difficult due to primer constraints. Finally, we demonstrated that these
416 assays can be performed on nucleic acids extracted from saliva samples to detect the presence
417 of specific SARS-CoV-2 mutations.

418 The R346, K444, N460, and F486 residues are locations of key mutations important in
419 neutralization escape, enhanced fusogenicity, and enhanced S protein processing. Structural

420 modeling suggests that R346T and K444T appear to disrupt salt bridge formation between S
421 protein and class III monoclonal antibodies (e.g. cilgavimab), lowering effectiveness (12, 29).
422 The N460K mutation has been shown to enhance S protein processing and is predicted to
423 facilitate a salt bridge and hydrogen bond formation between Spike and human ACE2,
424 enhancing cell fusion (30). The F486V mutation aided in evading serum neutralization by early
425 BA.5 lineages, but more recent lineages containing the F486S mutation are even more resistant
426 to neutralization (31). Beyond the mutations examined here, additional mutations at these loci
427 have been implicated in immune escape and are rising in frequency (11).

428 There are limitations to the use of dPCR for SNP identification. Since dPCR relies on sequence
429 homology between probes, primers, and template nucleic acids, it is susceptible to failure as
430 SARS-CoV-2 evolves mutations. There have been numerous reports of SARS-CoV-2 mutations
431 that cause failure on diagnostic RT-PCR assays (32-34). Mutations in other nucleotides of the
432 probe or primer binding regions will result in failed amplification, as observed with the K444
433 reference probe against the XBB lineage (**Fig 6A**), and could result in sequence misclassification.
434 Furthermore, caution must be exercised interpreting negative results of reactions containing
435 only a single probe for each SNP of interest (i.e. 6 mutant probe, 4 SNP assay; **Fig 6C**). Results
436 from lineages containing no mutations of interest, such as BA.2, are indistinguishable from
437 failed assays and samples with concentrations below the limit of detection. This limitation could
438 be overcome using a universally binding probe that would always provide a fluorescent
439 response but doing so would reduce the total number of SNP sites being interrogated in a single
440 reaction.

441 As new variants emerge, the effectiveness of current antibody therapies is at risk. At their
442 emergence, the initial Omicron variants were less sensitive to antibody treatments
443 bamlanivimab and etesevimab (joint administration) and REGEN-COV (casirivimab and
444 imdevimab), and their use was curtailed (35). More recent variants have caused the recall of
445 emergency use authorization for bebtelovimab, leaving Paxlovid (nirmatrelvir/ritonavir) and
446 remdesivir as preferred treatment options (36). These treatments are also at risk, as *in vitro*
447 analysis using a Vesicular Stomatitis Virus system has identified that Y54C, G138S, L167F,
448 Q192R, A194S and F305L mutations in nsp5 (3-cymotrypsin like protease) could result in
449 reduced Paxlovid efficacy (37). As demonstrated in this study, a similar dPCR approach could be
450 used to determine resistance to Paxlovid. Due to the very rapid development of resistance
451 mutations in SARS-CoV-2 (38) there is an increased need for versatile assays to guide patient
452 treatment and extend the use of life-saving therapeutics. The use of digital PCR to clarify active
453 infection (39), determine SARS-CoV-2 lineages, and pinpoint therapeutically relevant mutations
454 make it a well-suited technology for use in personalized diagnostics.

455

456

457 **ACKNOWLEDGEMENTS**

458 We thank the authors from originating laboratories responsible for obtaining the specimens
459 and the submitting laboratories where genetic sequence data were generated and shared via
460 the GISAID initiative, on which part of the research is based.

461

462 **FUNDING**

463 This research was funded by the Arizona Department of Health Services (CTR053916), the
464 Centers for Disease Control and Prevention (CDC BAA 75D30121C11084) and Tohono O’Odham
465 Nation (2020-01 ASU).

466

467 **ABBREVIATIONS**

468 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

469 Coronavirus Disease 2019 (COVID-19)

470 Reverse transcription-digital polymerase chain reaction (RT-dPCR)

471 Variant of concern (VOC)

472

473 **AVAILABILITY OF DATA AND MATERIALS**

474 Genome sequences have been deposited to the GISAID repository. Scripts for data curation can
475 be found on the Lim lab GitHub (<https://github.com/ASU-Lim-Lab/Absolute-Q>).

476

477 **COMPETING INTERESTS**

478 The authors declare no competing interests.

479

480 AUTHOR CONTRIBUTIONS

481 Conceptualization: S.C.H. and E.S.L.; data curation: S.C.H., L.A.H., M.B.L., J.C.H, M.F.S; formal
482 analysis: S.C.H., L.A.H., M.F.S.; funding acquisition: E.S.L.; investigation: S.C.H., L.A.H., M.L.,
483 M.F.S., J.C.H.; supervision: E.S.L.; writing – original draft: S.C.H. and E.S.L.; writing – review and
484 editing S.C.H. and E.S.L. All authors have read and agreed to the published version of the
485 manuscript.

486 REFERENCES

- 487 1. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, Fera D, Shafer RW. 2021.
488 The biological and clinical significance of emerging SARS-CoV-2 variants. *Nat Rev Genet* 22:757-
489 773.
- 490 2. Centers for Disease Control and Prevention. 2022. COVID Data Tracker, on US Department of
491 Health and Human Services, CDC. <https://covid.cdc.gov/covid-data-tracker>. Accessed 2022-12-
492 13.
- 493 3. World Health Organization. 2021. Enhancing Readiness for Omicron (B.1.1.529): Technical Brief
494 and Priority Actions for Member States. [https://www.who.int/docs/default-
495 source/coronaviruse/technical-brief-and-priority-action-on-omicron.pdf?sfvrsn=50732953_3](https://www.who.int/docs/default-source/coronaviruse/technical-brief-and-priority-action-on-omicron.pdf?sfvrsn=50732953_3).
496 Accessed 2022/11/14.
- 497 4. Du P, Gao GF, Wang Q. 2022. The mysterious origins of the Omicron variant of SARS-CoV-2.
498 *Innovation (Camb)* 3:100206.
- 499 5. Sun Y, Lin W, Dong W, Xu J. 2022. Origin and evolutionary analysis of the SARS-CoV-2 Omicron
500 variant. *J Biosaf Biosecur* 4:33-37.
- 501 6. Smith MF, Holland SC, Lee MB, Hu JC, Pham NC, Sullins RA, Holland LA, Mu T, Thomas AW, Fitch
502 R, Driver EM, Halden RU, Villegas-Gold M, Sanders S, Krauss JL, Nordstrom L, Mulrow M, White
503 M, Murugan V, Lim ES. in press. Baseline sequencing surveillance of public clinical testing,
504 hospitals, and community wastewater reveals rapid emergence of SARS-CoV-2 Omicron variant
505 of concern in Arizona, USA. *mBio*.
- 506 7. Zhang X, Wu S, Wu B, Yang Q, Chen A, Li Y, Zhang Y, Pan T, Zhang H, He X. 2021. SARS-CoV-2
507 Omicron strain exhibits potent capabilities for immune evasion and viral entrance. *Signal*
508 *Transduct Target Ther* 6:430.
- 509 8. McCallum M, Czudnochowski N, Rosen LE, Zepeda SK, Bowen JE, Walls AC, Hauser K, Joshi A,
510 Stewart C, Dillen JR, Powell AE, Croll TI, Nix J, Virgin HW, Corti D, Snell G, Veesler D. 2021.
511 Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement. *Science*
512 375:864-868.
- 513 9. Chen J, Wang R, Gilby NB, Wei GW. 2022. Omicron Variant (B.1.1.529): Infectivity, Vaccine
514 Breakthrough, and Antibody Resistance. *J Chem Inf Model* 62:412-422.
- 515 10. Cao Y, Jian F, Wang J, Yu Y, Song W, Yisimayi A, Wang J, An R, Chen X, Zhang N, Wang Y, Wang P,
516 Zhao L, Sun H, Yu L, Yang S, Niu X, Xiao T, Gu Q, Shao F, Hao X, Xu Y, Jin R, Shen Z, Wang Y, Xie

- 517 XS. 2022. Imprinted SARS-CoV-2 humoral immunity induces converging Omicron RBD evolution.
518 bioRxiv doi:10.1101/2022.09.15.507787.
- 519 11. Focosi D, McConnell S, Casadevall A. 2022. The Omicron variant of concern: Diversification and
520 convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies. *Drug*
521 *Resist Updat* 65:100882.
- 522 12. Qu P, Evans JP, Faraone JN, Zheng YM, Carlin C, Anghelina M, Stevens P, Fernandez S, Jones D,
523 Lozanski G, Panchal A, Saif LJ, Oltz EM, Xu K, Gumina RJ, Liu SL. 2022. Enhanced neutralization
524 resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2. *Cell*
525 *Host Microbe* doi:10.1016/j.chom.2022.11.012.
- 526 13. US FDA. 2022. FDA announces bebtelovimab is not currently authorized in any US region.
527 [https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-](https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region)
528 [currently-authorized-any-us-region](https://www.fda.gov/drugs/drug-safety-and-availability/fda-announces-bebtelovimab-not-currently-authorized-any-us-region). Accessed 2022-12-11.
- 529 14. Butchbach ME. 2016. Applicability of digital PCR to the investigation of pediatric-onset genetic
530 disorders. *Biomol Detect Quantif* 10:9-14.
- 531 15. Navarro E, Serrano-Heras G, Castano MJ, Solera J. 2015. Real-time PCR detection chemistry. *Clin*
532 *Chim Acta* 439:231-50.
- 533 16. Kutyaev IV, Afonina IA, Mills A, Gorn VV, Lukhtanov EA, Belousov ES, Singer MJ, Walburger DK,
534 Lohov SG, Gall AA, Dempcy R, Reed MW, Meyer RB, Hedgpeth J. 2000. 3'-minor groove binder-
535 DNA probes increase sequence specificity at PCR extension temperatures. *Nucleic Acids Res*
536 28:655-61.
- 537 17. Jiang L, Lin R, Gallagher S, Zayac A, Butchbach MER, Hung P. 2020. Development and validation
538 of a 4-color multiplexing spinal muscular atrophy (SMA) genotyping assay on a novel integrated
539 digital PCR instrument. *Sci Rep* 10:19892.
- 540 18. Sedlak RH, Cook L, Cheng A, Magaret A, Jerome KR. 2014. Clinical utility of droplet digital PCR for
541 human cytomegalovirus. *J Clin Microbiol* 52:2844-8.
- 542 19. Lo YM, Lun FM, Chan KC, Tsui NB, Chong KC, Lau TK, Leung TY, Zee BC, Cantor CR, Chiu RW.
543 2007. Digital PCR for the molecular detection of fetal chromosomal aneuploidy. *Proc Natl Acad*
544 *Sci U S A* 104:13116-21.
- 545 20. Caduff L, Dreifuss D, Schindler T, Devaux AJ, Ganesanandamoorthy P, Kull A, Stachler E,
546 Fernandez-Cassi X, Beerenwinkel N, Kohn T, Ort C, Julian TR. 2022. Inferring transmission fitness
547 advantage of SARS-CoV-2 variants of concern from wastewater samples using digital PCR,
548 Switzerland, December 2020 through March 2021. *Euro Surveill* 27.
- 549 21. ARTIC Network. 2022. [artic-network/primer-schemes/nCoV-2019](https://github.com/artic-network/primer-schemes/tree/master/nCoV-2019/V4). [https://github.com/artic-](https://github.com/artic-network/primer-schemes/tree/master/nCoV-2019/V4)
550 [network/primer-schemes/tree/master/nCoV-2019/V4](https://github.com/artic-network/primer-schemes/tree/master/nCoV-2019/V4). Accessed 2022-12-01.
- 551 22. Li H. 2013. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM.
552 arXiv 1303.3997.
- 553 23. Castellano S, Cestari F, Faglioni G, Tenedini E, Marino M, Artuso L, Manfredini R, Luppi M, Trenti
554 T, Tagliafico E. 2021. iVar, an Interpretation-Oriented Tool to Manage the Update and Revision
555 of Variant Annotation and Classification. *Genes (Basel)* 12.
- 556 24. Rambaut A, Holmes EC, O'Toole A, Hill V, McCrone JT, Ruis C, du Plessis L, Pybus OG. 2020. A
557 dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. *Nat*
558 *Microbiol* 5:1403-1407.
- 559 25. Schaffer AA, Hatcher EL, Yankie L, Shonkwiler L, Brister JR, Karsch-Mizrachi I, Nawrocki EP. 2020.
560 VADR: validation and annotation of virus sequence submissions to GenBank. *BMC Bioinformatics*
561 21:211.
- 562 26. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, Sagulenko P, Bedford T, Neher
563 RA. 2018. Nextstrain: real-time tracking of pathogen evolution. *Bioinformatics* 34:4121-4123.

- 564 27. Chen C, Nadeau S, Yared M, Voinov P, Xie N, Roemer C, Stadler T. 2021. CoV-Spectrum: Analysis
565 of Globally Shared SARS-CoV-2 Data to Identify and Characterize New Variants. *Bioinformatics*
566 38:1735-7.
- 567 28. Jessen R, Nielsen L, Larsen NB, Cohen AS, Gunalan V, Marving E, Alfaro-Nunez A, Polacek C,
568 Danish C-GC, Fomsgaard A, Spiess K. 2022. A RT-qPCR system using a degenerate probe for
569 specific identification and differentiation of SARS-CoV-2 Omicron (B.1.1.529) variants of
570 concern. *PLoS One* 17:e0274889.
- 571 29. Wang Q, Li Z, Ho J, Guo Y, Yeh AY, Mohri H, Liu M, Wang M, Yu J, Shah JG, Chang JY, Herbas F,
572 Yin MT, Sobieszczyk ME, Sheng Z, Liu L, Ho DD. 2022. Resistance of SARS-CoV-2 omicron
573 subvariant BA.4.6 to antibody neutralisation. *Lancet Infect Dis* 22:1666-1668.
- 574 30. Qu P, Evans JP, Zheng YM, Carlin C, Saif LJ, Oltz EM, Xu K, Gumina RJ, Liu SL. 2022. Evasion of
575 neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant. *Cell Host Microbe* 30:1518-
576 1526 e4.
- 577 31. Sheward DJ, Kim C, Fischbach J, Sato K, Muschiol S, Ehling RA, Bjorkstrom NK, Karlsson
578 Hedestam GB, Reddy ST, Albert J, Peacock TP, Murrell B. 2022. Omicron sublineage BA.2.75.2
579 exhibits extensive escape from neutralising antibodies. *Lancet Infect Dis* 22:1538-1540.
- 580 32. Amato L, Jurisic L, Puglia I, Di Lollo V, Curini V, Torzi G, Di Girolamo A, Mangone I, Mancinelli A,
581 Decaro N, Calistri P, Di Giallonardo F, Lorusso A, D'Alterio N. 2021. Multiple detection and
582 spread of novel strains of the SARS-CoV-2 B.1.177 (B.1.177.75) lineage that test negative by a
583 commercially available nucleocapsid gene real-time RT-PCR. *Emerg Microbes Infect* 10:1148-
584 1155.
- 585 33. Holland SC, Bains A, Holland LA, Smith MF, Sullins RA, Mellor NJ, Thomas AW, Johnson N,
586 Murugan V, Lim ES. 2022. SARS-CoV-2 Delta Variant N Gene Mutations Reduce Sensitivity to the
587 TaqPath COVID-19 Multiplex Molecular Diagnostic Assay. *Viruses* 14.
- 588 34. Vanaerschot M, Mann SA, Webber JT, Kamm J, Bell SM, Bell J, Hong SN, Nguyen MP, Chan LY,
589 Bhatt KD, Tan M, Detweiler AM, Espinosa A, Wu W, Batson J, Dynerman D, Wadford DA,
590 Puschnik AS, Neff N, Ah Yong V, Miller S, Ayscue P, Tato CM, Paul S, Kistler AL, DeRisi JL, Crawford
591 ED. 2020. Identification of a Polymorphism in the N Gene of SARS-CoV-2 That Adversely Impacts
592 Detection by Reverse Transcription-PCR. *J Clin Microbiol* 59.
- 593 35. National Institutes of Health. 2022. Anti-SARS-CoV-2 Monoclonal Antibodies.
594 [https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-](https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/anti-sars-cov-2-mono-clonal-antibodies/)
595 [products/anti-sars-cov-2-mono-clonal-antibodies/](https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/anti-sars-cov-2-mono-clonal-antibodies/). Accessed
596 36. US FDA. 2022. Coronavirus (COVID-19) Update: FDA Limits Use of Certain Monoclonal
597 Antibodies to Treat COVID-19 Due to the Omicron Variant. [https://www.fda.gov/news-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-mono-clonal-antibodies-treat-covid-19-due-omicron)
598 [events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-mono-clonal-](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-mono-clonal-antibodies-treat-covid-19-due-omicron)
599 [antibodies-treat-covid-19-due-omicron](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-mono-clonal-antibodies-treat-covid-19-due-omicron). Accessed 2022-12-10.
- 600 37. Heilmann E, Costacurta F, Volland A, von Laer D. 2022. SARS-CoV-2 3CLpro mutations confer
601 resistance to Paxlovid (nirmatrelvir/ritonavir) in a VSV-based, non-gain-of-function system.
602 *BioRxiv* doi:10.1101/2022.07.02.495455.
- 603 38. Rockett R, Basile K, Maddocks S, Fong W, Agius JE, Johnson-Mackinnon J, Arnott A, Chandra S,
604 Gall M, Draper J, Martinez E, Sim EM, Lee C, Ngo C, Ramsperger M, Ginn AN, Wang Q, Fennell M,
605 Ko D, Lim HL, Gilroy N, O'Sullivan MVN, Chen SC, Kok J, Dwyer DE, Sintchenko V. 2022.
606 Resistance Mutations in SARS-CoV-2 Delta Variant after Sotrovimab Use. *N Engl J Med* 386:1477-
607 1479.
- 608 39. Hwang HS, Lo CM, Murphy M, Grudva T, Gallagher N, Luo CH, Robinson ML, Mirza A, Conte M,
609 Conte A, Zhou R, Vergara C, Brooke CB, Pekosz A, Mostafa HH, Manabe YC, Thio CL, Balagopal A.
610 2022. Characterizing SARS-CoV-2 transcription of subgenomic and genomic RNAs during early
611 human infection using multiplexed droplet digital PCR. *J Infect Dis* doi:10.1093/infdis/jiac472.

612

613

614

615 **FIGURE LEGENDS**

616 **Fig 1:** Digital PCR assay for the determination of the Delta, Omicron BA.1, and Omicron BA.2

617 lineages. (A) Schematic showing annealing locations of primers (black arrows) and probes

618 (colored boxes) on the SARS-CoV-2 genome. (B) Representative fluorescence intensities of dPCR

619 microchambers for synthetic DNA constructs. Positive microchambers are those exceeding

620 fluorescence thresholds (shaded regions). (C) Number of positive microchambers (maximum

621 number of chambers is 20480) resulting from each saliva sample. Samples are grouped by

622 Illumina sequencing lineage determination and sorted by positive microchamber count of the

623 respective lineage-specific probe. Dotted line indicates the positive threshold value (9

624 microchambers).

625 **Fig 2:** Digital PCR assay for the determination of the Omicron BA.1, and Delta or Omicron BA.2

626 lineages. (A) Schematic showing annealing locations of primers (black arrows) and probes

627 (colored boxes) on the SARS-CoV-2 genome. (B) Representative fluorescence intensities of dPCR

628 microchambers for synthetic DNA constructs. Positive microchambers are those exceeding

629 fluorescence thresholds (shaded regions). (C) Number of positive microchambers (maximum

630 number of chambers is 20480) resulting from each saliva sample. Samples are grouped by

631 Illumina sequencing lineage determination and sorted by positive microchamber count of the

632 respective lineage-specific probe. Dotted line indicates the positive threshold value (9
633 microchambers).

634 **Fig 3:** Phylogenetic distribution of mutations that evade therapeutic monoclonal antibodies. (A)
635 Phylogenetic tree of representative circulating sublineages. Colored circles indicate the
636 presence of a Spike RBD mutation found in at least 75% of sequences within that lineage.
637 Global frequency, phylogenetic distribution, and codon frequencies for R346T (B), K444T (C),
638 N460K (D), F486S (E), and F486V (F) mutations.

639 **Fig 4:** Digital PCR assay for the detection of mutations associated with therapeutic monoclonal
640 antibody evasion. (A) Schematic showing annealing locations of primers (black arrows) and
641 probes (colored boxes) on the SARS-CoV-2 genome. (B) Representative fluorescence intensities
642 of dPCR microchambers for synthetic DNA constructs. Positive microchambers are those
643 exceeding fluorescence thresholds (shaded regions).

644 **Fig 5:** Representative microchamber fluorescence intensities for synthetic DNA constructs from
645 multiplexed dPCR assays. (A) R346 and K444 combination assay. (B) N460 and F486
646 combination assay. (C) Combination assay using R346T, K444T, N460K (AAA and AAG codons),
647 F486S, and F486V mutation probes. Positive microchambers are those exceeding fluorescence
648 thresholds (shaded regions).

649 **Fig 6:** Representative microchamber fluorescence intensities for clinical saliva specimens from
650 multiplexed dPCR assays. (A) R346 and K444 combination assay. (B) N460 and F486
651 combination assay. (C) Combination assay using R346T, K444T, N460K (AAA and AAG codons),

652 F486S, and F486V mutation probes. Positive microchambers are those exceeding fluorescence
653 thresholds (shaded regions).

654 **Fig S1:** Failure frequency of probes (A) and primers (B) used in the *spike* RBD digital PCR assays.

655 **Table S1:** Digital PCR probe sequences and modifications

656 **Table S2:** Digital PCR primer sequences

657 **Table S3:** Digital PCR synthetic DNA templates used in

658 **Supplementary Dataset 1:** Number of positive wells passing threshold value and metadata for
659 each specimen in the Orf1ab_3395 assay

660 **Supplementary Dataset 2:** Number of positive wells passing threshold value and metadata for
661 each specimen in the spike 143 deletion assay

662 **Supplementary Dataset 3:** Number of positive wells passing threshold value and metadata for
663 each specimen in the R346/K444 combined assay

664 **Supplementary Dataset 4:** Number of positive wells passing threshold value and metadata for
665 each specimen in the N460/F486 combined assay

666 **Supplementary Dataset 5:** Number of positive wells passing threshold value and metadata for
667 each specimen in the 6 mutation probe assay